NCCN=National Comprehensive Cancer Network; NEJM=New England Journal of Medicine.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

*In a study of 1750 patients who died of CRC between 2006 and 2012.
†Data from real-world clinical settings between May 2022 and June 2024 based on Laboratory Developed Test (LDT) usage of Shield, prior to FDA approval.
‡Based on 2 studies. Study 1 compared screening completion with “usual careˮ (fecal immunochemical test [FIT] and colonoscopy), and an “interventionˮ (usual care + Shield) in over 1000 patients, age 45-75 years, who initially were offered but did not complete FIT in the previous 3 to 9 months at a large, integrated health system. Study 2 compared adherence to standard of care vs Shield use in <250 patients age 45-84 years at 2 primary care clinics affiliated with a large, not-for-profit integrated regional health system. All data based on LDT usage of Shield in 2022 and 2023 (Study 1) and 2024 (Study 2), prior to FDA approval.